Brind.

Arvinas and Pfizer are jointly developing vepdegestrant for breast cancer and seeking FDA acceptance for the NDA.

1 report, 1 independent Updated Aug 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Arvinas (United States)Pfizer FDA

Keep exploring

The entities involved

Arvinas (United States)
company in New Haven, United States

Nothing else this week.
Pfizer
American multinational pharmaceutical and biotechnology corporation
- Pfizer and AT&T are discussed as blue-chip stocks as of June 30, 2026.19:27
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.14:45
FDA
- FDA issued an Early Alert regarding a device issue involving Edwards Lifesciences.19:23
- FDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.15:21

Related events

Coverage

Newest first; wire copies grouped

Aug 9GlobeNewswireArvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – Filing based on pivotal Phase 3 VERITAC-2 clinical trial